Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci148 in nAMD, DME, and RVO
NCT07817615Phase 1Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GenSci148 in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 40 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
GenSci148
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT07817615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817615.